The drug is intended to treat acute bacterial skin and skin structure infections caused by certain susceptible bacteria like Staphylococcus aureus, including methicillin-susceptible and methicillin-resistant strains, and Streptococcus pyogenes. The treatment is administered intravenously.
Dalvance is the first drug designated as a Qualified Infectious Disease Product to receive FDA approval. It was granted QIDP designation because it is an antibacterial or antifungal human drug intended to treat serious or life-threatening infections. As a QIDP, the drug was also given priority review.
More Articles on Quality:
Despite Guidelines, Antibiotics Prescribed at High Rate for Bronchitis
New Pathogen-Identification Method Leads to Cost Savings: Study
Kaiser South Sacramento Patients Potentially Exposed to Whooping Cough
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
